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Abstract
Objective: To assess the predictive potential of the complete response pattern
from the University of Pennsylvania Smell Identification Test for the diagnosis
of Parkinson’s disease. Methods: We analyzed a large dataset from the Arizona
Study of Aging and Neurodegenerative Disorders, a longitudinal clinicopathological study of health and disease in elderly volunteers. Using the complete
pattern of responses to all 40 items in each subject’s test, we built predictive
models of neurodegenerative disease, and we validated these models out of
sample by comparing model predictions against postmortem pathological diagnosis. Results: Consistent with anatomical considerations, we found that the
specific test response pattern had additional predictive power compared with a
conventional measure – total test score – in Parkinson’s disease, but not Alzheimer’s disease. We also identified specific test questions that carry the greatest
predictive power for disease diagnosis. Interpretation: Olfactory ability has typically been assessed with either self-report or total score on a multiple choice
test. We showed that a more accurate clinical diagnosis can be made using the
pattern of responses to all the test questions, and validated this against the
“gold standard” of pathological diagnosis. Information in the response pattern
also suggests specific modifications to the standard test that may optimize predictive power under the typical clinical constraint of limited time. We recommend that future studies retain the individual item responses for each subject,
and not just the total score, both to enable more accurate diagnosis and to
enable additional future insights.
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Introduction
Olfactory decline is a hallmark of both normal aging and
neurodegenerative diseases including Alzheimer’s disease
(AD) and Parkinson’s disease (PD). In PD, in particular,
olfactory dysfunction may precede the motor symptoms
of the disease by up to 7 years.1 Indeed, during the earliest premotor stages of PD, there is associated pathology
in olfactory-related areas.2 Recently, the movement disorders society created research criteria for the diagnosis of
prodromal PD,3 with olfactory loss being one biomarker.
While the main pathological indicator of PD is intraneuronal aggregation of a-synuclein into Lewy bodies, there
are other synucleinopathies that have also been associated
with olfactory dysfunction, including dementia with Lewy
bodies (DLB) and incidental Lewy body disease (ILBD).4–6
Thus, in many cases PD and related disorders might be
thought of as diseases of olfaction before they afflict other
brain areas. To this end the unified staging system for
Lewy body disorders has Stage I as being “olfactory bulbonly” pathology.7 Olfactory dysfunction is thus the
proverbial “canary in the coal mine” for PD. Since early
clinical diagnosis of PD by standard neurological examination is unreliable,8 this motivates the possibility of
improving clinical diagnosis by making better use of
potentially informative olfactory information. It may also
help to distinguish PD from other disorders that have a
motor but not necessarily olfactory component.
Here we consider the possibility that early diagnosis of
PD might be possible using olfactory testing. Previous
studies have shown that clinically diagnosed PD is associated with olfactory dysfunction, most using the now common University of Pennsylvania Smell Identification Test
(UPSIT) multiple choice test.6,9 Such testing is critical for
assessing olfactory dysfunction, since self-report can be
unreliable.10 However, the only information typically
retained from an UPSIT test – the total score – may be a
crude measure for guiding diagnosis; while the mean total
score of the PD subpopulation is lower than in healthy
subjects,9 the sensitivity and specificity of the total score
in distinguishing PD from non-PD-related olfactory deficits may not be high enough, or early enough in disease
progression, to be clinically valuable.11 But what if the
pattern of olfactory decline due to PD differs from that
due to other age-related pathologies or to normal aging?
Specifically, what if the total UPSIT score masks a particular response pattern of correct and incorrect answers on
individual test questions that has predictive power
exceeding that of the total score, or could be useful in
cases where the total score is not predictive at all? If this
were true, a subset of UPSIT test questions motivated by
the response patterns associated with specific phenotypic
subpopulations could be targeted to patients in the clinic
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to gain more information in less time than a traditional
40-question UPSIT would allow. While abbreviated versions of the UPSIT do exist,12,13 the specific composition
of questions on these minitests has not been pathologically validated to justify their use in specific disease diagnosis. Here we add pathological validation of disease
phenotypes by leveraging the power of the Brain and
Body Donation Program (BBDP) dataset from the Arizona Study of Aging and Neurodegenerative Disorders
(AZSAND).14 First, it contains neuropathological postmortem information about each subject, providing a
diagnostic gold standard that overcomes the limited accuracy of a purely clinical diagnosis. This also allows related
diseases to be identified and predicted that either do not
show up in clinical assessment, that may be mistaken for
PD in the clinic, or that otherwise confound analysis. Second, in some cases it contains longitudinal information
(not explored here), including subjects’ itemized UPSIT
responses during the course of aging and disease progression. Third, it contains abundant related data that can be
used to identify confounds and isolate the specific contribution of measured olfactory dysfunction to the predictive power of the UPSIT response pattern.
We previously used these data to show a strong association between olfactory dysfunction – as measured by
total UPSIT score – and pathological diagnosis of PD and
ILBD, as confirmed in postmortem examination.6 Here
we extend this result to show that the specific pattern of
UPSIT responses contains even greater diagnostic power
than the total score alone. We also isolate the specific test
questions with the greatest diagnostic power for PD,
opening the door to future variants of the test that focus
exclusively on these questions.

Material and Methods
Data
All data were obtained from the Banner Sun Health
Research Institute Brain and Body Donation Project
(BBDP, https://www.brainandbodydonationprogram.org),
in association with the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND), a longitudinal
research study of elderly individuals living in Maricopa
County, Arizona, USA. Both antemortem clinical and
postmortem neuropathological data were available for
N = 198 (N = 86 females) deceased individuals who took
at least one UPSIT, and reflect data available through
March 2016. Age at death was 86.4  8.0 years. Subjects
greater than 90 years of age at time of death were
assigned an age of 95 in this dataset to protect anonymity. Some subjects took the UPSIT on multiple occasions,
but only the last UPSIT prior to death for each subject
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(2.5  2.0 years prior) was used here for classification.
Age at time of last UPSIT ranged from 54 to 95; counts
of final clinicopathological diagnoses6 are provided in
Table 1. The BBDP has enrollment criteria that enrich for
certain disease phenotypes; consequently the abundance
of both neurodegenerative disease and olfactory dysfunction are unlikely to reflect an age-matched distribution
from the wider community. In particular, healthy, normosmic individuals are undersampled in this study. All
subjects signed written informed consent approved by the
Banner Institutional Review Board. All data are available
to other researchers upon request.

remaining 20%, with this repeated 100 times with unique,
random train/test splits. ROC curves were produced on
the ensemble test set performance, and smoothed using
Gaussian kernel density estimation with a bandwidth of
0.2. Statistical significance for differences between ROC
curves was computed using an analogue of the Mann–
Whitney U statistic.15 For Figure 3 we used only the LDA
for reasons of coefficient interpretability. Coefficients for
the shuffled data in Figure 3 were obtained by shuffling
the diagnostic labels (i.e., PD = 0 or PD = 1) across subjects and fitting the classifier. This was performed 100
times to produce the null distribution of coefficients.

Statistics and predictive modeling

Results

Data obtained from the BBDP were analyzed using the
Python packages pandas and sklearn, and all analysis code
including recipes for reproduction of all figures and tables
is available at http://github.com/rgerkin/UPSIT. Because
the number of features used for prediction is high, we use
machine learning techniques to outperform standard multivariate regression and to minimize the possibility of
overfitting. Each possible UPSIT question response (a, b,
c, or d) was coded as a mutually exclusive input feature
to the classifier. There were thus five possible outcomes,
corresponding to one of the four responses, or to nonresponse. In preliminary work we found that support vector
machines (SVM) and a linear discriminant analysis
(LDA) each outperformed all other classification techniques on a wide range of problems related to this dataset
(using default sklearn parameters). We consequently used
a simple average of these two for all classification work
reported in Figures 1–3. The classifier was only trained
on a subset of the data, and then assessed on the remaining data (“out-of-sample”) to avoid overfitting and to
increase the likelihood that the results would generalize
beyond the data collected to date. Specifically, the classifier was trained on 80% of the data and tested on the

As the AZSAND is an active program, here we update
and confirm our previous results6 using a larger sample
size (Fig. 1A). We then constructed a classifier (Material
and Methods) and used it with a small subset of clinical
data to predict the pathological phenotype subsequently
determined by postmortem brain examination.
The classifier was provided with basic information like
the age and gender of the subjects at the time of clinical
assessment, as well as a subjective, qualitative self-assessment of olfactory function (“normal,” “reduced,” or “absent”) (Fig. 1B, black line). It also had access to either the
total UPSIT score (Fig. 1B, blue line), to the correctness
of each response (red line), or to the response itself (i.e.,
which multiple choice answer the subject selected,
magenta line). All classifiers using UPSIT information
were substantially more accurate (P < 0.001, Mann–Whitney U test) than the one using only qualitative olfactory
information, but none of the former were significantly
different from each other. However, this initial analysis
included subjects with pathologically confirmed comorbidities such as AD or other dementing disorders, which
are extremely likely to reduce UPSIT performance for reasons unrelated to olfactory dysfunction. After removing
these subjects from the analysis, leaving a “pure” PD and
non-PD sample (Fig. 1C), we retrained the classifier, and
found that the specific response pattern on the UPSIT test
provided significantly more diagnostic information than
the total score alone (Fig. 1D, AUC = 0.89 vs.
AUC = 0.76, P < 0.01). For one cutoff, the classifier using
the itemized response data approached sensitivity 80%
with specificity 80%.
There were no significant differences in the performance of the best classifier between male and female subjects (AUC = 0.89  0.05 vs. 0.89  0.06, P > 0.5);
classification was slightly more accurate for subjects
younger than the median age than for those that were
older (AUC = 0.91  0.05 vs. 0.85  0.06, P = 0.06), but
this difference was not significant. We also considered the

Table 1. Number of subjects with each postmortem diagnosis.
Diagnosis

N

AD only
PD only
PSP only
AD and PD
AD and PSP
PD and PSP
All of these
None of these

54
23
7
7
3
2
0
80

AD, Alzheimer’s disease; PD, Parkinson’s disease; PSP, progressive
supranuclear palsy.
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(A)

(B)

(C)

(D)

Figure 1. The specific UPSIT response pattern is diagnostic of PD. (A) Subjects with pathologically confirmed PD (red) had poorer overall
performance on the UPSIT than subjects who did not (black) (see also Driver-Dunckley et al.6). (B) The UPSIT test score (blue) improves diagnostic
accuracy of PD relative to a simple qualitative self-assessment of olfactory dysfunction (black). For this sample in which subjects with comorbidities
were included, additional details of the UPSIT test performance, such as the correctness of each response (red), the position of the responses
(green), or the pattern of responses (magenta), did not further improve accuracy. Area under the curve (AUC) for each classifier is provided in
the legend. (C) Similar to A, but excluding subjects with pathologically confirmed dementias such as AD, reflecting a “pure” sample of PD versus
non-PD. (D) Using the pure sample from (C), a classifier that uses the individuals’ responses to each of the 40 UPSIT questions significantly
outperforms one that only uses the total number of questions answered correctly.

possibility that the value of the itemized response data
might be driven by a preference for responses occurring
in a certain position in the list of possible responses, for
example, certain subjects might always choose multiple
choice answer “d.” However, a classifier exploiting this
possibility rather than using the full response pattern
actually performed worse (AUC = 0.68) than one using
only the total score alone (AUC = 0.76). Consequently, a
simple order effect cannot explain our results.
PD might specifically impair olfactory performance by
damaging brain areas in the early stages of olfactory processing, whereas the mechanism by which AD could
impair olfaction might be more general, due to

involvement of higher order brain regions. Consequently
we should expect that, while AD should reduce UPSIT
test performance for cognitive reasons (Fig. 2A), the test
itself is unlikely to provide especially useful diagnostic
information. Consistent with this hypothesis, using a
“pure” AD sample (i.e., no other significant confounding
pathologies) we found that no variation of the classifier
had impressive performance (Fig. 2B). To confirm that
these subpopulations were nonetheless distinguishable in
principle, we added the total score of a Mini-Mental Status Examination (MMSE) test to the classifier, which
resulted in classification performance for AD that was
similar to that obtained for PD using the UPSIT response
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pattern alone (Fig. 2C), and which largely obviated the
value of the UPSIT in AD diagnosis.
The motor symptoms that initially suggest the possibility of PD can also be produced by other movement
disorders, such as progressive supranuclear palsy (PSP).
This can make accurate diagnosis challenging, especially
in the early stages of disease.8 Since PSP is not known
for specific olfactory pathology, this suggests that the
UPSIT test might be used for differential diagnosis of
PD versus PSP, as demonstrated previously.16 We offer
preliminary support for the possibility that the specific
pattern of responses on the test can be used in a similar way to distinguish PD from PSP (AUC = 0.91);
however, sample size for this particular comparison is
limited in our dataset and so this result should be considered speculative.
Since the specific pattern of responses on the test
appeared to be more informative than the total score, we
asked whether some questions and/or responses might be
more informative than others, which might suggest more
rapid and efficient diagnostics that rely on only those. We
fit the classifier to the entire dataset of nondemented subjects, and then projected the data back onto the first principal dimension of the resulting fit. This allowed us to
visualize a “score” for each subject associated with a likelihood of PD (Fig. 3A). Because this score is fit to the
entire dataset, it is overly optimistic about the capacity to
cleanly distinguish PD from non-PD in practice, but it
nonetheless represents the best fit to the data. We then
examined the coefficients associated with each possible
UPSIT question response (40 questions 9 4 responses per
question = 160 coefficients) to see if some were especially
informative. To compute a threshold for “informative,”
we also shuffled the diagnostic labels and recomputed the
same coefficients. Since classification after shuffling represents fitting to statistical noise, the distribution of coefficients so obtained represents a null hypothesis that we
can use to assess significance. The true distribution had a
longer tail than the one obtained via shuffling (Fig. 3B),
suggesting that some of the largest coefficients were
meaningfully informative. We then plotted these coefficients and identified those that exceeded the 99th percentile of the null distribution. While only 1.6 coefficients
would be expected to exceed this threshold by chance,
we observed 12 (Fig. 3C). These coefficients correspond
to particular “wrong” answers on individual UPSIT questions, specifically questions 1, 2, 5, 7, 9, 19, 21, 23, 26, 31,
32, and 40. They do not reflect getting the wrong answer
per se, but to a specific wrong answer, elaborated in
Table 2. Eleven of these 12 were still significant at
P < 0.05 after controlling for false discovery rate.
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(A)

(B)

(C)

Figure 2. AD diagnosis is not improved by using the UPSIT. (A)
Subjects with AD perform more poorly on the UPSIT than controls. (B)
Adding the UPSIT still results in weak classification performance.
(C) Adding the MMSE substantially improves classification
performance.
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(B)

(C)

Figure 3. Specific incorrect responses inform PD diagnosis. (A) A classifier fit to the entire nondemented subject sample and mapped onto the
fit’s first principal dimension distinguishes PD (red) from control (black) subjects. (B) The coefficients (corresponding to the informativeness of each
possible response to each UPSIT question) of the classifier have a distribution with a longer tail than coefficients obtained using the same classifier
applied to the same data with diagnostic labels shuffled. (C) All 160 coefficients (4 per UPSIT question) are plotted, with green corresponding to
the correct answer to each question, and red to each of the three incorrect answers. The 95th and 99th percentiles of the shuffled distribution
are shown as dashed lines.

Discussion
Olfactory dysfunction is a hallmark of some neurodegenerative diseases including PD. Previous studies have
reported that poor performance on the UPSIT is correlated with PD, but it was previously unclear if this test
had enough predictive power to be of clinical value. Part
of this uncertainty originates from the use of a purely
clinical diagnosis of PD as a gold standard, which may be
inaccurate especially in the early stages of the diseases.8
Here we overcame this issue using a postmortem pathological assessment of subjects as a gold standard, made
possible by the ongoing AZSAND and BBDP.14
The UPSIT is typically scored as the total number of
questions answered correctly, which is reasonable as a
measure of total olfactory discrimination ability. However, because a low score might arise from either PD,
another neurodegenerative disease, a peripheral olfactory
disorder, dementia, or from normal aging, it may be difficult to use that score to make a specific clinical diagnosis.
We had hypothesized that the specific pattern of incorrect
questions might help to disambiguate these cases; this

Table 2. The 12 UPSIT question/response pairs with significant diagnostic power, showing the correct odor and the incorrect response
that distinguishes PD from controls.
Q#

Correct

Response

PD

CTRL

1
2
5
7
9
19
21
23
26
31
32
40

Pizza
Bubble gum
Motor oil
Banana
Leather
Chocolate
Lilac
Peach
Pineapple
Paint thinner
Grass
Peanut

Peanuts
Dill pickle
Grass
Motor oil
Apple
Black pepper
Chili
Pizza
Onion
Watermelon
Gingerbread
Root beer

0.22
0.22
0.43
0.48
0.26
0.35
0.39
0.13
0.30
0.22
0.39
0.22

0.07
0.06
0.14
0.07
0.04
0.04
0.06
0.01
0.06
0.03
0.17
0.06

For each phenotype the proportion of subjects providing that specific
incorrect response is shown. UPSIT, University of Pennsylvania Smell
Identification Test; PD, Parkinson’s disease.

might be because PD subjects answer specific questions
incorrectly that other subjects do not, or because they
answer them incorrectly in specific ways. For example,
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confusing the odor of lavender with pizza might reflect
a different underlying pathology than confusing it with
motor oil. We provided support for this hypothesis by
showing that a classifier constructed from the specific
pattern of responses (and nonresponses) to test questions significantly outperformed (out-of-sample) one
that used only the total score. In contrast, we did not
observe such improved performance when the same
method was applied to the diagnosis of AD in our sample, which we had hypothesized due to the fact that
smell deficits in AD are not necessarily specific defects
of the olfactory system.
What specific features of the UPSIT response pattern are
useful for PD diagnosis? Can these be exploited to construct a more parsimonious test to more quickly collect
the most diagnostically relevant information about olfactory dysfunction? We found that 12 incorrect responses
(one for each of 12 questions) were significantly predictive
of PD, whereas fewer than 2 were expected by chance.
While we identified specific incorrect responses to those
questions that were most informative, these responses may
not reflect such a detailed perceptual deficit; for example,
the particular incorrect responses observed may have
resulted from a tendency for subjects to have similar guessing strategies when they could not identify the odor. Consequently, it remains possible that it is not the specific
responses that are important, but simply which questions
were answered incorrectly, regardless of how they were
answered. Indeed, the performance of the classifier that
used only the correctness of the answers performed nearly
as well as the one that used the detailed response pattern
(Fig. 1D). Naturally, classification performance would still
decrease if only these responses are considered, because
even responses with a nonsignificant impact individually
are still likely to provide valuable information in the aggregate. However, in clinical settings where time or fatigue is
a concern, an abbreviated version of the test focusing on
those 12 questions might be a reasonable or even superior
alternative to the B-SIT test otherwise used in that scenario,12 at least for the diagnosis of PD. This also suggests that
differential diagnosis might be improved by an adaptive
version of the UPSIT, where questions are presented out of
order, and the subsequent questions determined in part by
the subject’s response to the previous questions. This
would maximize the amount of useful diagnostic information collected in a given amount of time in the clinic, and
make partially completed tests more interpretable. Naturally, the diagnostic power of any biomarker is best understood in the context of what other potentially more
accurate or less expensive biomarkers already provide. It
remains to be seen whether patterns of dysosmia specific
to and diagnostic of PD are correlated with or captured by
other available biomarkers.
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Because hyposmia is considered a risk factor for PD, it
has been used as an enrollment criterion for studies of the
development of the disease in otherwise healthy adults.17
Abbreviated questionnaires have struggled to identify preclinical PD18; the results shown here suggest that the predictive power of such questionnaires might be further
optimized based on the diagnostic value of specific questions. However, this hope is predicated on the assumption
that clinical and preclinical PD share a similar detailed
olfactory phenotype, differing mostly in magnitude rather
than having different specific patterns of dysosmia, an idea
which has not been thoroughly investigated.
Finally, we strongly recommend that clinicians and
researchers retain the specific responses (a, b, c, d, or no
response) for each of the 40 UPSIT questions for each
subject, and not just the subjects’ total scores. This more
refined data will enable future investigations of the diagnostic power of olfactory testing, including on specific
subpopulations.
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